HIV treatment for teens and children
Part of Immune system & allergy, Infections clinical trials.
This trial tests a new combination of HIV medicines for children and teenagers under 18 who weigh at least 35 kilograms (about 77 pounds). It aims to see if this treatment is safe and effective for young people who have not been treated before or who are already on a stable HIV treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 18 years old
- You weigh at least 35 kilograms (about 77 pounds)
- You have HIV-1 (the most common type of HIV)
- You either have not taken HIV medicines before, or you have been on a stable HIV treatment for at least 3 months
- You do not have hepatitis (a liver infection)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different HIV medicines in children and teenagers to find safer, more effective options. It aims to improve viral suppression and overall health for young people living with HIV.
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
This Phase 2 study tests doravirine (a type of HIV medicine) in children with HIV who are about 4 weeks to under 12 years old and weigh under 45 kg. It aims to see whether this regimen can control the virus safely, and some children may continue into an extension if they benefit.
This study tests whether a long-acting injectable HIV medicine (given every couple of months) and teen support clubs can help adolescents stay healthy and engaged in care. If you are a teen living with HIV, this trial may offer a more convenient treatment option.
This study tests a new combination medicine for people with HIV who have never taken treatment. It aims to see if it is safe and helps reduce the amount of virus in the blood.
This study tests a daily combination of two medicines, rifapentine and isoniazid, to prevent tuberculosis (TB) in children under 13 years old. It aims to see if this short treatment is safe and works well for kids, including those living with HIV.
Hear when a new HIV-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.